Inside this Issue ISSUE 3 | VOLUME 4
»
» » »
How have the findings of recent, large systematic reviews reassured the rheumatology community regarding its current approach to treating patients with rheumatoid arthritis (RA)? What correlations have recently been found between the use of biologic disease modifying anti‑rheumatic drugs and specific adverse events? How has the recent introduction of biosimilars in the United States impacted patients with RA? How might some of the new and late-stage agents under development offer new opportunities for the treatment of RA?
Earn CE Credits with Rheumatology Nurse Practice!
RELEASE: SEPT 21, 2017 / EXPIRES: SEPT 21, 2018
All issues of Rheumatology Nurse Practice will be CE certified in 2017 for the first time. See method of participation details inside on page 3. EDUCAT ION A L P L A N N I N G CO M M ITTE E :
Jacqueline Fritz RN, MSN, CNS, RN-BC
Elizabeth Kirchner CNP, RN-BC
Board Certified in Rheumatology Nursing
Board Certified in Rheumatology Nursing
Critical Care & Rheumatology Specialist Medical Advancement Center Cypress, California
Nurse Practitioner Cleveland Clinic Cleveland, Ohio
Iris Zink MSN, NP, RN-BC
Cathy Patty-Resk MSN, RN, CPNP-PC
Board Certified in Rheumatology Nursing
Certified Pediatric Nurse Practitioner in Primary Care
Nurse Practitioner Lansing Rheumatology Lansing, Michigan
Pediatric Nurse Practitioner Division of Rheumatology, Children's Hospital of Michigan, Detroit, Michigan
RNSnurse.org